Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

NCT05878769 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05878769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05878769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 28, 2023
Completion date
June 30, 2027
Enrollment
2,000 (estimated)
Sites
481

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease